A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

Trial Profile

A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Ataluren (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 06 Mar 2017 According to an European Medicines Agency media release dated March 2017, PTC Therapeutics International Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for Translarna to be used to treat cystic fibrosis. This decision was based on the data from this trial which failed to show that Translarna was more effective than placebo at improving lung function or reducing flare-ups in the overall study population.
    • 10 Jun 2016 New analyses from this trial were presented at the 39th European Cystic Fibrosis Conference, according to a PTC Therapeutics media release.
    • 30 Sep 2015 According to a PTC Therapeutics media release, the EMA has validated the submission of a variation for a new indication for ataluren [Translarna] for the treatment of nonsense mutation cystic fibrosis for patients not taking chronic inhaled aminoglycoside antibiotics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top